hero image

BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS FEBRUARY 13, 2024

January 12, 2024 News Release

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report fourth quarter and full year 2023 financial results Tuesday, February 13, 2024, before the financial markets open.

Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen’s website at investors.biogen.com. An archived version of the webcast will be available for at least 90 days following the presentation.

About Biogen
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease, the first treatment to target a genetic form of ALS, the first oral treatment approved for postpartum depression, and the first approved treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - FacebookLinkedIn, X, YouTube.

 

Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442

thumb
March 4, 2024
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

New data advances understanding of new approaches to treating Alzheimer’s disease Research on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced it will present new data from its Alzheimer’s disease

thumb
February 26, 2024
Biogen to Participate in the TD Cowen 44th Annual Health Care Conference

Cambridge, MA, - -  Biogen Inc. (Nasdaq: BIIB) announced today that Michael McDonnell, Chief Financial Officer, Priya Singhal, M.D., M.P.H., Head of Development, and Alisha Alaimo, Head of North America, will participate in a fireside chat during the TD Cowen 44th Annual Health Care Conference.